Parathyroid hormone-related peptide (1-36)

Drug Profile

Parathyroid hormone-related peptide (1-36)

Alternative Names: hPTHrP-(1-36); PTHrP-(1-36)

Latest Information Update: 20 Nov 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Yale University
  • Developer Ostotrophin LLC; University of Pittsburgh; Yale University
  • Class
  • Mechanism of Action Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Malignant hypercalcaemia; Postmenopausal osteoporosis

Most Recent Events

  • 27 Jul 2006 No development reported - Clinical-Phase-Unknown for Postmenopausal osteoporosis in USA (SC)
  • 04 Mar 2003 A study has been added to the adverse events and Musculoskeletal and Women's Health therapeutic trials sections
  • 05 Feb 2003 Clinical trials in Postmenopausal osteoporosis in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top